Zacks Investment Research on MSN
AXS stock moves above 50 & 200-day SMA: Buy, sell or stay invested?
Shares of Axis Capital Holdings AXS have gained momentum. The stock is trading above its 50 and 200-day simple moving average ...
Zacks Investment Research on MSN
AXSM up on FDA priority review to AXS-05 sNDA in Alzheimer's agitation
Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...
Axsome Therapeutics (AXSM) has quickly moved onto investors' radar after the FDA accepted a priority review for AXS-05 in Alzheimer’s agitation and signaled support for an NDA filing for narcolepsy ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...
New Drug Application (NDA) submission on track for January 2026NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: ...
AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two ...
Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved ...
AXS, the global advanced ticketing and live event technology company, has announced two key leadership appointments as part of its continued technology transformation and global growth. Nikhil Bobde ...
Axie Infinity (AXS) has dropped by roughly 90% after peaking out at $172 in November 2021. AXS’s sharp correction has made it one of the worst-performing digital assets among the top-ranking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback